BioNTech SE BNTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 732.90% | -117.58% | -42.23% | -228.35% | -115.41% |
| Total Depreciation and Amortization | 163.41% | 434.71% | 215.10% | -248.79% | 197.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.52% | 21.78% | -538.99% | 1,852.50% | 113.16% |
| Change in Net Operating Assets | -197.48% | 17.11% | 117.23% | 64.13% | 203.89% |
| Cash from Operations | -116.37% | -92.66% | 40.04% | 172.95% | 229.95% |
| Capital Expenditure | 7.86% | -106.47% | -29.14% | -3.63% | 47.56% |
| Sale of Property, Plant, and Equipment | -49.08% | 596.83% | 255.76% | -6.39% | 928.02% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 196.17% | -32.57% | 119.00% | -575.37% | -1,263.36% |
| Cash from Investing | 185.94% | -59.29% | 136.36% | -590.61% | -592.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 2.61% | -28.57% | 13.04% | -160.27% | -45.57% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1,891.28% | -736.02% | 312.69% | -113.92% | -54.80% |
| Foreign Exchange rate Adjustments | 109.16% | -136.76% | 76.52% | -88.76% | -894.06% |
| Miscellaneous Cash Flow Adjustments | 1,130.65% | -53.42% | 196.02% | 201.28% | -97.28% |
| Net Change in Cash | 356.33% | -340.33% | 495.07% | -2,022.83% | 75.03% |